Cocktail Event – August 30, 2017

BELLUS Health is a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need. Its pipeline of projects includes BLU-5937 for chronic cough potentially best-in-class drug for multi billion dollar chronic cough market. BELLUS maintains a balanced portfolio in several other partnered clinical-stage drug development programs. President and CEO, Roberto Bellini leads a management team with a strong record of execution. TSX:BLU (Recent SP: $.38)

BELLUS Health Presentation August 2017

Perimeter Medical Imaging develops, patents, and commercializes advanced surgical imaging tools that allow surgeons, radiologists and pathologists to better assess microscopic tissue structures during surgical procedures. Perimeter’s Optical Tissue Imaging System (OTIS™) is the only solution that provides clinicians with an ultra-high resolution image of the entire surface of an excised tissue specimen, providing accurate information in real time, and enabling better surgical decisions and outcomes.